Development of a Validated RP-HPLC/UV Method for the Quantitative Determination of Tyrosine Kinase RET Inhibitor: Selpercatinib in Capsule Formulation
Abstract
A validated RP-HPLC/UV method was developed to estimate the selpercatinib in capsules. The wavelength chosen for detection was at 248 nm. The RP-HPLC separation was carried out using a Hypersil ODS C18 column (250×4.6 mm, 5 μm) with a mobile phase consisting of 0.2% TFA (pH 6.5) and acetonitrile in a ratio of 70:30 v/v. The flow rate was set at 1 ml/min. The retention time for selpercatinib was determined to be 3.012 min. Linearity was detected within the concentration range of 2.5-15 μg/mL for selpercatinib. The approach has been confirmed to be linear, accurate, precise, robust, and has established limits of detection and quantitation. The established procedure was uncomplicated, cost-effective, and suitable for the routine analysis of selpercatinib in capsule dosage form.
Keywords: Selpercatinib, RP-HPLC and Validation.
Keywords:
Selpercatinib, RP-HPLC, Method development, ValidationDOI
https://doi.org/10.22270/jddt.v14i7.6702References
Markham A. Selpercatinib: first approval. Drugs. 2020; 80(11):1119-24. https://doi.org/10.1007/s40265-020-01343-7 PMid:32557397 PMCid:PMC7716849
Subbiah V, Yang D, Velcheti V, Drilon A, Meric-Bernstam F. State-of-the-art strategies for targeting RET-dependent cancers. Journal of Clinical Oncology. 2020; 38(11):1209-21. https://doi.org/10.1200/JCO.19.02551 PMid:32083997 PMCid:PMC7145587
Le D, Konda B. Selpercatinib for adult patients with locally advanced or metastatic RET-altered solid tumors. Expert Review of Anticancer Therapy. 2023; 23(11):1117-22. https://doi.org/10.1080/14737140.2023.2267754 PMid:37795873
Eli Lilly. RETEVMOTM (selpercatinib): US prescribing information. https://pi.lilly.com/us/retevmo-uspi.pdf. Accessed 2024.
Nie T, Syed YY. Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC. Targeted Oncology. 2023;18(1):169-76. https://doi.org/10.1007/s11523-022-00935-5 PMid:36422787
Gulikers JL, van Veelen AJ, Sinkiewicz EM, de Beer YM, Slikkerveer M, Stolk LM, Tjan‐Heijnen VC, Hendriks LE, Croes S, van Geel RM. Development and validation of an HPLC-MS/MS method to simultaneously quantify brigatinib, lorlatinib, pralsetinib and selpercatinib in human K2‐EDTA plasma. Biomedical Chromatography. 2023; 37(6):e5628. https://doi.org/10.1002/bmc.5628 PMid:36941218
Katta SR, Thakre G. Characterization of Degradation Products of Selpercatinib by Mass Spectrometry: Optimization of Stability-Indicating HPLC Method for Separation and Quantification of Process Related Impurities of Selpercatinib. Asian journal of chemistry. 2024; 36(2):341-52. https://doi.org/10.14233/ajchem.2024.30884
Singamsetty N, Sundararajan R. Analytical Method Development and Validation for Determination of Selpercatinib by Using RP-HPLC. Int. J. Res. Pharm. Sci. 2021; 12 (931): 931-939. https://doi.org/10.26452/ijrps.v12i1.4471
Sumalatha Ch, Srinivas M, Jitendar KM, Development of a Robust and Reliable RP-HPLC Method for the Estimation of Finerenone in Tablet Dosage Form. International Journal of Drug Delivery Technology. 2024; 14(2):703-708. https://doi.org/10.25258/ijddt.14.2.15
Sai KE, Srinivas M, Kumari BU, Sumalatha C, Madhavi A. Development and Validation of an HPLC Method for the Determination of Lobeglitazone in Bulk and in Tablet Formulation. International Journal of Pharmaceutical Investigation. 2024; 14(1). https://doi.org/10.5530/ijpi.14.1.26
Harshita D, Srinivas M, Kumari BU, Sumalatha C, Umadevi R. Establishment and Validation of a High-performance Liquid Chromatography Technique for Quantifying Dalbavancin in Injectable Formulations. Asian Journal of Pharmaceutical Research and Health Care. 2023; 15(4):385-92. https://doi.org/10.4103/ajprhc.ajprhc_112_23
ICH. Validation of analytical procedure: Methodology International Conference on Harmonization. ICH harmonised tripartite guideline - validation of analytical procedures: text and methodology Q2(R1). ICH, Geneva, Switzerland, 2005.
Published
Abstract Display: 219 
PDF Downloads: 160 PDF Downloads: 78 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.